Beigene (BGNE) Stock Rating Reaffirmed by Cowen

Beigene (NASDAQ:BGNE)‘s stock had its “buy” rating restated by stock analysts at Cowen in a research report issued on Monday, January 8th.

A number of other equities research analysts have also issued reports on BGNE. Maxim Group reissued a “buy” rating and set a $120.00 target price (up previously from $77.00) on shares of Beigene in a research note on Thursday, September 28th. ValuEngine downgraded shares of Beigene from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. BidaskClub upgraded shares of Beigene from a “hold” rating to a “buy” rating in a report on Friday, January 5th. Robert W. Baird restated a “neutral” rating and set a $83.00 price target (up previously from $58.00) on shares of Beigene in a report on Tuesday, November 14th. Finally, Zacks Investment Research upgraded shares of Beigene from a “hold” rating to a “buy” rating and set a $115.00 target price on the stock in a report on Tuesday, October 3rd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. Beigene has an average rating of “Hold” and a consensus price target of $96.67.

Shares of Beigene (NASDAQ BGNE) traded up $1.44 during trading hours on Monday, reaching $103.28. 140,600 shares of the company were exchanged, compared to its average volume of 180,956. The company has a market capitalization of $4,695.83, a PE ratio of -79.45 and a beta of -1.03. Beigene has a 1 year low of $31.70 and a 1 year high of $118.95. The company has a quick ratio of 9.27, a current ratio of 9.33 and a debt-to-equity ratio of 0.20.

Beigene (NASDAQ:BGNE) last posted its quarterly earnings data on Monday, November 13th. The company reported $2.54 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $2.31. The firm had revenue of $220.21 million during the quarter, compared to analyst estimates of $1.55 million. During the same period in the prior year, the business posted ($1.08) EPS. research analysts predict that Beigene will post -2.04 earnings per share for the current fiscal year.

In other Beigene news, CMO Jane Huang sold 600 shares of the business’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $85.00, for a total value of $51,000.00. Following the completion of the transaction, the chief marketing officer now directly owns 264,900 shares of the company’s stock, valued at $22,516,500. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO John Oyler sold 150,957 shares of the business’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $80.50, for a total transaction of $12,152,038.50. Following the completion of the transaction, the chief executive officer now directly owns 491,891 shares of the company’s stock, valued at $39,597,225.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 483,482 shares of company stock worth $42,139,474. 19.90% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently bought and sold shares of BGNE. SG Americas Securities LLC bought a new stake in shares of Beigene during the second quarter worth approximately $111,000. Quantbot Technologies LP bought a new stake in Beigene in the third quarter valued at approximately $160,000. Profund Advisors LLC bought a new stake in Beigene in the second quarter valued at approximately $248,000. Teachers Retirement System of The State of Kentucky bought a new stake in Beigene in the third quarter valued at approximately $248,000. Finally, Aperio Group LLC bought a new stake in Beigene in the third quarter valued at approximately $301,000. 55.32% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This article was posted by BBNS and is the property of of BBNS. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://baseballnewssource.com/markets/cowen-reiterates-buy-rating-for-beigene-bgne/1819156.html.

About Beigene

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Analyst Recommendations for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.